Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Nov 24, 2010 3:17pm
696 Views
Post# 17752546

What does form NI44-101 mean ?

What does form NI44-101 mean ?If you go to www.sedar.com and look up the Public Company Documents for Quetzel, you will note that on Nov.12, 2010, QEI filed notification that they '' intend to be qualified to file a short form prospectus under NI44-101 '' '' This notice does not evidence the Issuer's intent to file a short form prospectus ''

So QEI has taken the necessary step to raise more capital.
Now while I agree that a dilution is unwelcome. It is not allways bad news for shareholders.

Look at Alange Energy. ALE has 747 million shares out. However, if you research the company's history, you will see that once they had a significant discovery with prospective future cash flow, they quickly raised more money to accelerate their drilling program. And since they are drilling in '' a highly prospective area '' , ( like QEI ) their subsequent success has led them to a 2010 exit rate of over 10,000 bopd production.

At today's share price of .54, ALE has a market capitalization of 403 million dollars
At today's share price of .22, QEI has a market cap of 71 million dollars.

And just maybe.....................QEI has aquired enough knowledge about this new reservoir to allow a more rapid plan for development well drilling...................... resulting in much greater production much more quickly than previously thought by management.

As events unfold over the next 6 months or so, let us hope that the market capitalization of QEI sees a muliple of what it is today.



Bullboard Posts